Hansoh Pharma (03692): Apatinib Mesylate Tablets Approved for Listing by the UK Medicines and Healthcare products Regulatory Agency.
Hangsen Pharmaceuticals (03692) announced that the group's innovative drug Amelutinib Mesylate Tablets (UK trade name: Aums...
HANSOH PHARMA (03692) announced that its innovative drug Aumseqa (alectinib hydrochloride tablets, known as Aumseqa in the UK) has been approved for sale by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Aumseqa is indicated for use as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations, as well as for the treatment of adult patients with locally advanced or metastatic NSCLC who are positive for the EGFR T790M mutation.
Related Articles
Is AI growth momentum slowing down? Broadcom Inc. (AVGO.US) reported record high revenue in Q2 but Q3 guidance fell short of the most optimistic expectations.
The stablecoin giant Circle (CRCL.US) is massively popular on the market and injects a strong stimulant into the US IPO market.
Concept tracking of Hong Kong stocks | US steel and aluminum tariffs doubled to 50% Steel and aluminum prices skyrocket Institutions: Focus on strategic metal investment opportunities (With concept stocks)
Is AI growth momentum slowing down? Broadcom Inc. (AVGO.US) reported record high revenue in Q2 but Q3 guidance fell short of the most optimistic expectations.
The stablecoin giant Circle (CRCL.US) is massively popular on the market and injects a strong stimulant into the US IPO market.
Concept tracking of Hong Kong stocks | US steel and aluminum tariffs doubled to 50% Steel and aluminum prices skyrocket Institutions: Focus on strategic metal investment opportunities (With concept stocks)
